Sanofi pulls Nurix’s STAT6 degrader after a brief first-in-human run
Sanofi has stopped development of SAR448272, a STAT6 degrader from Nurix that entered phase 1 testing only two months earlier. The decision ends a short-lived clinical push into type 2 inflammatory disease and leaves the program as a reminder of how quickly large pharmaceutical companies can reset priorities when early human data, portfolio pressure, or commercial logic no longer align.
The move is abrupt. Sanofi took the candidate into the clinic in August, triggering a $10 million milestone payment to Nurix, then discontinued the study and terminated the program by early November. For a molecule meant to exploit protein degradation rather than conventional inhibition, the stop comes before the field has had much chance to learn whether the approach can deliver a meaningful therapeutic edge in human immune disease.
A collaboration built around targeted protein degradation
Sanofi and Nurix have been linked since 2019, when the French company paid $55 million to begin working with the biotech on new uses for E3 ligases, the cellular machinery that tags specific proteins for destruction. A year later, Sanofi added another $22 million to expand the collaboration. In 2024, the deal widened again to include STAT6, a transcription factor tied to type 2 inflammation and a logical target for diseases driven by allergic and eosinophilic pathways.
The partnership deepened again last year, when Sanofi secured two additional degrader programs from the same alliance, one against STAT6 and one against an undisclosed target. The repeated investment suggested confidence in Nurix’s discovery platform and in the broader promise of induced protein degradation outside oncology. For immunology, the appeal is obvious: instead of blocking a pathway with partial receptor occupancy, a degrader aims to eliminate the protein itself, potentially producing a more durable biological effect.
In theory, removing STAT6 should blunt signaling downstream of cytokines central to type 2 inflammation. In practice, the step from mechanistic elegance to a usable medicine is often narrow, especially when the target sits inside a complex immune network where on-target biology and tolerability can still fail to translate into a differentiated clinical profile.
Phase 1 entry was followed by a fast reversal
Nurix had framed the August trial launch as validation of its DEL-AI discovery platform, arguing that the system was generating differentiated degrader medicines for immunology. The milestone payment that followed reflected the usual economics of partnered drug development: first human dosing creates value, even when the dataset is still thin.
Then Sanofi reversed course.
Nurix disclosed the discontinuation in a press release, saying the company had been informed that Sanofi was stopping trial work and ending SAR448272 development. No detailed rationale was included, and no safety signal, efficacy shortfall, or pharmacokinetic failure was laid out publicly. Still, the speed of the decision suggests that whatever Sanofi saw across its internal review was enough to close the book on the asset before the program could generate a meaningful phase 1 footprint.
For a first-in-human immunology program, that is a harsh outcome. It also means the public record offers little insight into whether the issue was biology, molecule design, dose selection, commercial fit, or the broader strategy around Sanofi’s inflammation portfolio.
Portfolio discipline is increasingly driving Sanofi’s inflammation bets
The decision lands against a backdrop of portfolio reshaping under Sanofi chief executive Belén Garijo, M.D., Ph.D. Recent changes trimmed the company’s pipeline and removed several assets, including amlitelimab, balinatunfib and itepekimab. The company’s chief financial officer recently told journalists there were no plans for major restructuring, but the sequence of decisions still points to a sharper internal filter around what deserves continued capital.
For a large drugmaker, that scrutiny is not academic. Type 2 inflammatory disease remains commercially attractive, yet the category is crowded and biologically sophisticated, with established standards already occupying important treatment niches. Any new degrader would need to show a clear clinical advantage, whether through deeper pathway suppression, improved convenience, or activity in patients who do not respond to existing biologics.
The challenge is especially pronounced for a first-generation degrader in immunology. Unlike oncology, where protein degradation has already established a foothold, inflammatory disease demands long-term tolerability, predictable exposure, and enough efficacy to justify shifting patients away from entrenched therapies. A brief early-stage trial may be enough to test whether the biology is workable, but it is rarely enough to prove a commercial case on its own.
Nurix keeps multiple shots on goal despite the setback
Nurix moved quickly to stress that the company remains financially stable and still has three clinical-stage programs across its wholly owned and partnered portfolio, alongside a preclinical pipeline. Arthur Sands, M.D., Ph.D., named bexobrutideg, the Roche-partnered BTK degrader in phase 3 development for chronic lymphocytic leukemia; a Gilead-partnered IRAK4 degrader in phase 1 for rheumatoid arthritis; and the company’s wholly owned CBL-B inhibitor NX-1607, also in phase 1 for various cancers.
One program disappearing does not erase the strategic value of the broader platform. Yet the loss of a Sanofi-sponsored immunology asset does remove a visible validation point for Nurix’s attempt to move degradation chemistry beyond hematologic malignancy and into inflammatory disease. In that sense, the termination carries significance beyond a single candidate: it narrows one of the clearest tests of whether Nurix can convert platform science into partnered, human-stage immunology products.
Sanofi still has the option to take additional Nurix compounds into the clinic, and Nurix said it would remain eligible for milestones if that happens. But the near-term message is straightforward. A promising partnership in protein degradation can still lose momentum quickly when the first clinical checkpoint fails to justify further investment.
The unanswered question is not whether the alliance produced a clinic-ready program once. It did. The question is whether Sanofi’s decision reflects a molecule-specific issue with SAR448272, or a broader reassessment of how much risk the company wants to carry in type 2 inflammation as its portfolio is rebalanced around higher-confidence assets and long-range commercial pressure.